Are the vertigo, fatigue, confusion, blurred vision, and lethargy that began after two weeks of solifenacin (antimuscarinic) therapy likely adverse effects of the medication?

Yes, these symptoms are highly likely related to solifenacin and warrant immediate evaluation and potential discontinuation.

The constellation of dizziness, fatigue, confusion, vision changes, and lethargy after two weeks of solifenacin therapy represents classic antimuscarinic central nervous system (CNS) adverse effects that are well-documented with this medication.

Direct Evidence from FDA Drug Label

The FDA label for solifenacin explicitly warns about antimuscarinic CNS adverse reactions, stating that "a variety of CNS antimuscarinic adverse reactions have been reported, including headache, confusion, hallucinations and somnolence" 1. The label specifically instructs clinicians to "monitor patients for signs of antimuscarinic CNS adverse reactions, particularly after beginning treatment" and advises that "if a patient experiences antimuscarinic CNS adverse reactions, consider dose reduction or drug discontinuation" 1.

Vision changes (blurred vision) are listed as a common adverse effect occurring in 3.8-4.8% of patients on solifenacin versus 1.8% on placebo 1. Dizziness occurs in approximately 1.8-1.9% of patients 1. Fatigue is documented at 2.1% in the 10mg group versus 1.1% on placebo 1.

Supporting Clinical Evidence

High-quality guideline evidence from the American College of Physicians confirms that solifenacin causes "dry mouth, blurred vision, constipation" as the most commonly reported adverse effects 2. The guidelines note that while solifenacin had the lowest discontinuation rate due to adverse effects among antimuscarinics (NNTH 78), adverse effects still occur and are clinically significant 2.

A case report specifically documented solifenacin-induced delirium and hallucinations in an 80-year-old patient, with immediate symptom improvement after discontinuation 3. This demonstrates that CNS effects can be severe and reversible.

Clinical Action Algorithm

Immediate steps:

1. Discontinue solifenacin immediately - The FDA label explicitly recommends dose reduction or discontinuation for CNS adverse reactions 1

2. Assess severity of confusion and vision changes - Rule out other acute causes (infection, metabolic derangement, stroke) but recognize the temporal relationship strongly suggests drug causation

3. Monitor for symptom resolution - CNS effects should improve within days of discontinuation given solifenacin's 33-85 hour half-life 4

4. Consider alternative therapy if OAB treatment still needed:

   • Beta-3 agonist (mirabegron) - does not have anticholinergic CNS effects 5, 6
   • Behavioral interventions (bladder training, pelvic floor muscle training) 7
   • Darifenacin - has lower CNS penetration and was successfully used in the case report after solifenacin-induced delirium 3

Important Caveats

Risk factors that increase CNS adverse effects:

• Elderly patients (this patient's age is not specified but is critical)
• Concomitant use of other CNS-active medications
• Renal or hepatic impairment (increases solifenacin exposure 2-fold) 4
• Concomitant CYP3A4 inhibitors (doubles exposure) 1

Do not restart solifenacin if symptoms resolve after discontinuation, as this confirms causation. The combination of multiple CNS symptoms (confusion, lethargy, dizziness) plus peripheral antimuscarinic effects (vision changes) creates a clear adverse effect profile that contraindicates continued use 1.

The 2-week timeframe is consistent with accumulation to steady-state levels, making drug-related adverse effects highly plausible. Solifenacin crosses the blood-brain barrier and can affect CNS muscarinic receptors despite being marketed as bladder-selective 4, 8.